Astr.Ns

Astrazeneca maintains a strong liquidity position with INR 5,093.30 crore in cash and equivalents, representing 33.55% of total assets. The company's liquidity FPT (free cash flow to total liabilities) stands at 12.47%, well above the pharmaceutical industry median of 8.2%. The current ratio of 1.91 indicates a solid short-term liquidity buffer, while the debt-to-equity ratio of 0.05 reflects a conservative capital structure with long-term debt accounting for just 4.63% of total liabilities.

Profitability metrics show Astrazeneca generates a return on equity (ROE) of 15.02% and return on assets (ROA) of 7.62%, both exceeding the industry medians of 12.4% and 5.8% respectively. The gross margin of 41.4% (INR 7,104.10 crore gross profit on INR 17,162.90 crore revenue) is in line with sector norms, but the operating margin of 6.85% (INR 1,175.60 crore) lags behind the 8.2% median, suggesting potential pressure on operating leverage.

Geographically, Astrazeneca derives 42% of revenue from North America, 28% from Europe, and 18% from Asia-Pacific, with the remaining 12% from other regions. The company's oncology segment contributes 38% of total revenue, followed by cardiovascular and metabolic (29%) and respiratory (23%). This segmental concentration creates exposure to regulatory and pricing pressures in key markets.

Looking ahead, revenue is projected to grow 6.2% in FY2024 and 4.8% in FY2025, driven by new oncology product launches and expanded market access in emerging markets. However, the company faces margin compression risks from generic competition in its respiratory portfolio and potential pricing pressures in the U.S.. Free cash flow is expected to remain stable at INR 939.80 crore, with capital expenditures limited to INR 17.50 crore as the company prioritizes R&D over CAPEX.

Risk factors include moderate liquidity risk due to low short-term debt exposure, but the company's low dilution risk (1.2% probability of near-term equity issuance) is supported by strong cash balances and no material shelf registration activity in the past 12 months. The ESG profile is strong, with a governance score of 75.26 and low controversy risk (84.38 score), but the company faces regulatory scrutiny in the EU over pricing practices.

Recent events include a Q2 2024 earnings call highlighting progress in oncology pipeline candidates and a July 2024 FDA approval for a new respiratory treatment. The company also announced a partnership with a European biotech firm for a novel autoimmune disease therapy in August 2024.